{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:12:56Z","timestamp":1761959576754,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.lrr.2021.100279","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T03:15:17Z","timestamp":1635822917000},"page":"100279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review"],"prefix":"10.1016","volume":"16","author":[{"given":"Abhay","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopisree","family":"Peringeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lrr.2021.100279_bib0001","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.lrr.2021.100279_bib0002","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Modern pathol. an official J. United States and Canadian Acad. Pathol., Inc"},{"issue":"9","key":"10.1016\/j.lrr.2021.100279_bib0003","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.lrr.2021.100279_bib0004","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.exphem.2008.04.017","article-title":"Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha","volume":"36","author":"Baumgartner","year":"2008","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.lrr.2021.100279_bib0005","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/j.leukres.2010.02.024","article-title":"Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib","volume":"34","author":"Ikezoe","year":"2010","journal-title":"Leuk Res."},{"issue":"12","key":"10.1016\/j.lrr.2021.100279_bib0006","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00432-013-1529-7","article-title":"Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome\/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study","volume":"139","author":"Hochhaus","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lrr.2021.100279_bib0007","first-page":"1321","volume":"44","author":"Love","year":"2012","journal-title":"The genetic landscape of mutations in Burkitt lymphoma. Nature genetics"},{"issue":"24","key":"10.1016\/j.lrr.2021.100279_bib0008","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2021.100279_bib0009","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2353\/jmoldx.2007.060196","article-title":"A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint","volume":"9","author":"Lambert","year":"2007","journal-title":"J. Mol. Diagn."},{"issue":"10","key":"10.1016\/j.lrr.2021.100279_bib0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/gcc.20359","article-title":"Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene","volume":"45","author":"Walz","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.lrr.2021.100279_bib0011","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1200\/JCO.2012.48.0665","article-title":"Successful Treatment With Imatinib in a Patient With Chronic Eosinophilic Leukemia Not Otherwise Specified","volume":"32","author":"Iurlo","year":"2014","journal-title":"J. Clinical Oncol."},{"key":"10.1016\/j.lrr.2021.100279_bib0012","first-page":"6","article-title":"Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)\/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia","volume":"5","author":"Su","year":"2016","journal-title":"Hum. Pathol. (N Y)"},{"issue":"10","key":"10.1016\/j.lrr.2021.100279_bib0013","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.lrr.2021.100279_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185602","article-title":"Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lrr.2021.100279_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048921000467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:25Z","timestamp":1761959305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048921000467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":15,"alternative-id":["S2213048921000467"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100279","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2021.100279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100279"}}